Premium
Development of monoclonal antibody imaging of metastatic prostatic carcinoma
Author(s) -
Meyers Frederick J.,
Denardo Sally J.,
Macey Daniel,
White Ralph Devere,
Unger Michael
Publication year - 1989
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990140303
Subject(s) - monoclonal antibody , medicine , antibody , prostate , carcinoma , immunoscintigraphy , antigen , prostate carcinoma , pharmacokinetics , pathology , prostate specific antigen , adjuvant , radioimmunotherapy , epithelioma , cancer research , oncology , cancer , immunology
Indium‐111‐labeled monoclonal antibody directed against prostate‐specific antigen was injected into ten patients with known prostatic carcinoma, nine with metastatic disease. The monoclonal antibody scan was compared to the standard technetium bone scan, and both were correlated to clinical status and to 2‐year follow‐up. The ratio of target‐to‐nontarget activity and pharmacokinetics of the radiolabeled antibody were determined. Based on these findings we are hopeful that modifications of this radiolabeled antibody approach may be used for staging and may be developed as a therapeutic adjuvant.